Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468)
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 4534
- Registration Number
- NCT00519857
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 207
- Registration Number
- NCT00516737
Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2152
- Registration Number
- NCT00511199
Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 121
- Registration Number
- NCT00511355
Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 48
- Registration Number
- NCT00511433
Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 110
- Registration Number
- NCT00511342
A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 256
- Registration Number
- NCT00496730
LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 201
- Registration Number
- NCT00496834
This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 310
- Registration Number
- NCT00491504
A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 994
- Registration Number
- NCT00489346
© Copyright 2024. All Rights Reserved by MedPath